Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
By Bhanvi Satija and Mariam Sunny (Reuters) -Novartis has agreed to buy Regulus (NASDAQ:RGLS) Therapeutics for up to $1.7...
By Bhanvi Satija and Mariam Sunny (Reuters) -Novartis has agreed to buy Regulus (NASDAQ:RGLS) Therapeutics for up to $1.7...
– France stocks were higher after the close on Wednesday, as gains in the Utilities, Healthcare and Industrials...
– Belgium stocks were higher after the close on Wednesday, as gains in the Healthcare, Utilities and Telecoms...
-- Alphabet Inc (NASDAQ:GOOGL) CEO Sundar Pichai defended Google’s search business in court Wednesday, warning that...
-- Seaport Research started coverage of the semiconductor sector with a cautious view, downgrading Nvidia...
By Nick Carey LONDON (Reuters) -Unable to predict the impact of U.S. President Donald Trump’s ever-changing trade war, Stellantis...
– Finland stocks were higher after the close on Wednesday, as gains in the Industrials, Oil & Gas and Consumer...
By Anuja Bharat Mistry (Reuters) -Norwegian Cruise Line Holdings missed estimates for first-quarter revenue and profit on...
MILAN (Reuters) -Eyewear maker EssilorLuxottica, whose brands include Ray-Ban, could move part of its production to the United...
(Reuters) -Nearly 450,000 customers in Pennsylvania were without power early on Wednesday, data from PowerOutage.us showed, a day...